TY - JOUR
T1 - The role of Panax ginseng in neurodegenerative disorders
T2 - mechanisms, benefits, and future directions
AU - Mehrnoosh, Faranak
AU - Rezaei, Dorsa
AU - Pakmehr, Seyed Abbas
AU - Nataj, Paria Ganji
AU - Sattar, Mustafa
AU - Shadi, Melina
AU - Ali-khiavi, Payam
AU - Zare, Farshad
AU - Hjazi, Ahmed
AU - Al-Aouadi, Raed Fanoukh Aboqader
AU - Sapayev, Valisher
AU - Zargari, Faranak
AU - Alkhathami, Ali G.
AU - Ahmadzadeh, Roya
AU - Khedmatgozar, Mohammad
AU - Hamzehzadeh, Sina
N1 - Publisher Copyright:
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2025.
PY - 2025/4
Y1 - 2025/4
N2 - Neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Amyotrophic lateral sclerosis (ALS), Multiple sclerosis (MS), and Huntington’s disease (HD) represent a growing global health challenge, especially with aging populations. Characterized by progressive neuronal loss, these diseases lead to cognitive, motor, and behavioral impairments, significantly impacting patients’ quality of life. Current therapies largely address symptoms without halting disease progression, underscoring the need for innovative, disease-modifying treatments. Ginseng, a traditional herbal medicine with well-known adaptogenic and neuroprotective properties, has gained attention as a potential therapeutic agent for neurodegeneration. Rich in bioactive compounds called ginsenosides, ginseng exhibits antioxidant, anti-inflammatory, and anti-apoptotic effects, making it a promising candidate for addressing the complex pathology of neurodegenerative diseases. Recent studies demonstrate that ginsenosides modulate disease-related processes such as oxidative stress, protein aggregation, mitochondrial dysfunction, and inflammation. In AD models, ginsenosides have been shown to reduce amyloid-beta accumulation and tau hyperphosphorylation, while in PD, they help protect dopaminergic neurons and mitigate motor symptoms. Ginseng’s effects in ALS, MS, and HD models include improving motor function, extending neuronal survival, and reducing cellular toxicity. This review provides a comprehensive overview of the neuroprotective mechanisms of ginseng, emphasizing its therapeutic potential across various neurodegenerative diseases and discussing future research directions for its integration into clinical practice.
AB - Neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Amyotrophic lateral sclerosis (ALS), Multiple sclerosis (MS), and Huntington’s disease (HD) represent a growing global health challenge, especially with aging populations. Characterized by progressive neuronal loss, these diseases lead to cognitive, motor, and behavioral impairments, significantly impacting patients’ quality of life. Current therapies largely address symptoms without halting disease progression, underscoring the need for innovative, disease-modifying treatments. Ginseng, a traditional herbal medicine with well-known adaptogenic and neuroprotective properties, has gained attention as a potential therapeutic agent for neurodegeneration. Rich in bioactive compounds called ginsenosides, ginseng exhibits antioxidant, anti-inflammatory, and anti-apoptotic effects, making it a promising candidate for addressing the complex pathology of neurodegenerative diseases. Recent studies demonstrate that ginsenosides modulate disease-related processes such as oxidative stress, protein aggregation, mitochondrial dysfunction, and inflammation. In AD models, ginsenosides have been shown to reduce amyloid-beta accumulation and tau hyperphosphorylation, while in PD, they help protect dopaminergic neurons and mitigate motor symptoms. Ginseng’s effects in ALS, MS, and HD models include improving motor function, extending neuronal survival, and reducing cellular toxicity. This review provides a comprehensive overview of the neuroprotective mechanisms of ginseng, emphasizing its therapeutic potential across various neurodegenerative diseases and discussing future research directions for its integration into clinical practice.
KW - Ginsenosides
KW - Neurodegenerative diseases
KW - Oxidative stress
KW - Panax Ginseng
UR - http://www.scopus.com/inward/record.url?scp=105003016505&partnerID=8YFLogxK
U2 - 10.1007/s11011-025-01610-0
DO - 10.1007/s11011-025-01610-0
M3 - Review article
C2 - 40232582
AN - SCOPUS:105003016505
SN - 0885-7490
VL - 40
JO - Metabolic Brain Disease
JF - Metabolic Brain Disease
IS - 4
M1 - 183
ER -